Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20

Citigroup analyst Yigal Nochomovitz has upgraded Arcturus Therapeutics (NASDAQ: ARCT) from Neutral to Buy. The price target for the stock has been raised significantly from $8 to $20.